Myomo Posts Record Q3 Revenue and Breakeven Adjusted EBITDA, But Cash Conversion Still Unproven

What happened

Myomo reported record revenue for Q3 2026 and achieved breakeven Adjusted EBITDA, citing operating leverage from its four strategic pillars. This follows a HOLD/NEUTRAL stance in the prior DeepValue report, which highlighted a 2024 net loss of $6.2 million and a 1H25 operating cash outflow of approximately $11.5 million against only $15.5 million in cash and short-term investments at mid-2025. The news indicates progress on reimbursement-driven adoption under Medicare’s brace benefit, but the truncated release does not disclose net income, cash flow, or ending cash balances. The adjusted EBITDA figure excludes stock compensation, depreciation, amortization, interest, and taxes, so it can diverge significantly from actual cash generation. As a result, the record revenue and breakeven metric are encouraging but do not by themselves confirm sustainable profitability or an extended cash runway.

Implication

Investors should view the record revenue and Adjusted EBITDA breakeven as a positive operational signal, but not yet a thesis-changing event because adjusted metrics can exclude significant cash expenses and working-capital needs. The company’s historical pattern of operating cash outflows and modest cash reserves means that a break-even quarter on an adjusted basis may not materially extend runway if reimbursement cycles remain long. Key confirmation points are the next quarterly filing’s cash balance, operating cash flow, and any commentary on payer approval rates and audit outcomes. If Q4 and full-year 2026 show net income positivity and positive operating cash flow, a re-rating toward a more constructive stance would be warranted; conversely, if Adjusted EBITDA breakeven is achieved only through non-cash adjustments or one-time items, the HOLD thesis remains intact. Maintain a high bar for evidence of durable unit economics and cash conversion before upgrading.

Thesis delta

The Q3 2026 print modestly strengthens the bull case by meeting a key profitability milestone on an adjusted basis, but it does not yet alter our HOLD/NEUTRAL judgment. We would upgrade to BUY only upon confirmation of positive GAAP net income and positive operating cash flow with a stable or growing cash balance. Until then, the same cash-burn and liquidity concerns flagged in the master report remain central.